Skip to main content
TipRanks
Go Ultimate75% OFF

Bicara Therapeutics Inc. (BCAX) AI Stock Analysis

93 Followers
BCAX

Bicara Therapeutics Inc.

(NASDAQ:BCAX)

Select Model
Rating:49Neutral
Price Target:$8.50â–¼(-12.82% Downside)
Action:reiterated
Date:11/10/26

The score is held down primarily by weak financial performance (pre-revenue with accelerating losses and cash burn) and bearish technicals (price below all key moving averages with negative MACD). These are partially offset by a constructive earnings-call outlook (pivotal trial progress, Breakthrough Therapy designation, and cash runway into 1H 2029), while valuation inputs are limited due to negative earnings and no dividend yield data.

Positive Factors
Durable Clinical EfficacyThe reported Phase Ib responses are both deep and durable, with substantial tumor shrinkage and nearly two years of median response duration. If confirmed in the pivotal program, this profile could support meaningful differentiation in HPV-negative head and neck cancer and strengthen the candidate’s clinical positioning.
Negative Factors
Pre-Revenue Loss ProfileWithout product revenue, Bicara’s financial performance is determined by research, development, and organizational spending rather than commercial execution. Losses have widened sharply over time, increasing the distance to self-funded operations and making future value increasingly dependent on successful clinical and regulatory outcomes.

Bicara Therapeutics Inc. (BCAX) vs. SPDR S&P 500 ETF (SPY)

-75%-50%-25%0%25%50%75%100%BCAX-39.74%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$647.28M
Dividend Yield
―
Average Volume (3M)
1.17M
Price to Earnings (P/E)
-2.8
Beta (1Y)
1.71
Revenue Growth
―
EPS Growth
-55.27%
Country
US
Employees
103
Sector
General
Sector Strength
55
Industry
Biotechnology

Bicara Therapeutics Inc. Business Overview & Revenue Model

Company Description

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors...

How the Company Makes Money

As a clinical-stage biotechnology company, Bicara Therapeutics’ primary economic activity is advancing drug candidates through discovery, preclinical development, and clinical trials rather than generating recurring revenue from product sales. Detail...

Bicara Therapeutics Inc. Earnings Call Summary

Earnings Call Date:Nov 09, 2026(Q3-2026)|% Change Since:12.72%|Next Earnings Date:Apr 01, 2027
Earnings Call SentimentPositive

The call was predominantly positive, driven by substantial pivotal-trial enrollment, plans for an interim overall survival analysis, encouraging and durable Phase Ib efficacy data, Breakthrough Therapy designation, commercial preparation, and a cash runway into the first half of 2029. The main negatives were sharply higher operating expenses, the absence of pivotal data to date, pending regulatory clarity, a competitive market, and the still-early, late-line status of the colorectal cancer program.

Positive Updates

Substantial Enrollment in FORTIFI-HN01
The pivotal FORTIFI-HN01 study has achieved substantial enrollment sufficient to enable a top-line interim analysis, which the company continues to expect in the middle of next year. Bicara also confirmed plans for an interim overall survival analysis and said the approximately 650-patient, HPV-negative-only study does not need to be upsized.

Negative Updates

Higher Research and Development Expenses
Third-quarter 2026 research and development expenses increased to $56.5 million from $33.0 million in the third quarter of 2025, an increase of approximately 71%. The company attributed the increase primarily to FORTIFI-HN01, FORTIFI-FLEX, Phase I/Ib dose-expansion cohorts, and higher personnel costs.

Company Guidance

Bicara expects top line interim analysis from FORTIFI-HN01 in the middle of next year and plans to incorporate an interim overall survival analysis, although it has not guided to when that will occur; the study is around 650 patients and the company does not expect to need to upsize it. CRC data are planned for presentation in January, FORTIFI-FLEX data are anticipated prior to the first approval, and its overall design remains unchanged. The company anticipates that overall operating expenses through year-end will remain consistent with its most recent quarterly results, while approximately $442.3 million in cash, cash equivalents and marketable securities provides cash runway into the first half of 2029. Bicara continues to view timing as less than a year between itself and petosemtamab.

Bicara Therapeutics Inc. Financial Statement Overview

Summary

Financial profile is pressured by being pre-revenue with rapidly widening losses and accelerating cash burn (TTM net loss about -$220.3M; operating cash flow about -$161.7M; FCF about -$162.8M), increasing financing/dilution risk. Offsetting this, leverage is minimal (about $0.9M debt vs. $409.4M equity) and the asset/equity base is sizeable, providing some balance-sheet flexibility despite deteriorating ROE (about -49.1% TTM).

Income Statement

12Very Negative

Balance Sheet

74Positive

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022
Income Statement
Total Revenue00000
Gross Profit00000
EBITDA-219.87M-137.63M-67.75M-51.96M-37.72M
Net Income-220.28M-137.95M-68.00M-51.98M-37.84M
Balance Sheet
Total Assets460.64M430.99M510.00M233.98M6.70M
Cash, Cash Equivalents and Short-Term Investments442.35M414.80M489.71M230.44M4.16M
Total Debt880.00K1.71M738.00K657.00K0
Total Liabilities51.23M29.54M18.12M15.47M23.98M
Stockholders Equity409.41M401.45M491.88M218.51M-17.28M
Cash Flow
Free Cash Flow-162.75M-107.11M-74.82M-46.21M-32.27M
Operating Cash Flow-161.73M-106.83M-74.75M-45.63M-32.08M
Investing Cash Flow-128.04M-318.45M-9,000-586.00K-192.00K
Financing Cash Flow200.12M32.26M334.03M272.50M31.70M

Bicara Therapeutics Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price9.75

Price Trends

50DMA16.57Negative
100DMA21.50Negative
200DMA20.80Negative

Market Momentum

MACD-2.14Negative
RSI33.17Neutral
STOCH57.38Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCAX, the sentiment is Negative. The current price of 9.75 is below the 20-day moving average (MA) of 11.86, below the 50-day MA of 16.57, and below the 200-day MA of 20.80, indicating a bearish trend. The MACD of -2.14 indicates Negative momentum. The RSI at 33.17 is Neutral, neither overbought nor oversold. The STOCH value of 57.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCAX.

Bicara Therapeutics Inc. Risk Analysis

Bicara Therapeutics Inc. disclosed 83 risk factors in its most recent earnings report. Bicara Therapeutics Inc. reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk
1.our existing business, could have a material adverse effect on our operating results, dilute our stockholders' ownership, increase our debt or cause us to incur significant expense.Q1, 2026

Bicara Therapeutics Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

BCAX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SRPTSRPT58Neutral$1.62B168.581.04%―-18.95%59.85%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
TSHATSHA54Neutral$1.32B-9.46-51.87%―-13.07%-23.02%
NTLANTLA49Neutral$1.38B-2.91-64.73%―-8.07%21.55%
BCAXBCAX49Neutral$647.28M-2.76-49.13%――-55.27%
WVEWVE47Neutral$566.05M-2.69-44.48%―-35.07%-45.17%
STOKSTOK46Neutral$1.74B-7.01-67.30%―-86.28%-634.38%

* General Sector Average

Performance Comparison

0%100%200%BCAXSRPTWVENTLASTOKTSHADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BCAX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BCAXBicara Therapeutics Inc.9.75-5.43-35.77%
SRPTSarepta Therapeutics Inc.15.13-1.26-7.69%
WVEWave Life Sciences Pte. Ltd2.87-4.01-58.28%
NTLAIntellia Therapeutics Inc9.861.6219.66%
STOKStoke Therapeutics26.63-1.85-6.50%
TSHATaysha Gene Therapies, Inc.4.060.051.25%

Bicara Therapeutics Inc. Corporate Events

Business Operations and Strategy

Bicara Therapeutics Secures Boston Headquarters Through Sublease

Positive
Aug 25, 2026

On August 21, 2026, Bicara Therapeutics Inc. entered into a sub-sublease agreement with Wayfair LLC to secure approximately 35,090 square feet of office space at 10 St. James Avenue in Boston for its new corporate headquarters. The lease term will co...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 10, 2026